In Celexir’s specialized category, Cecropins (e.g., B, p17, LHRH variants) are positioned strictly for antimicrobial and immunology research, not routine clinical use. They are insect-derived antimicrobial peptides evaluated primarily in vitro and in murine models, where they serve as tools for studying host defense and candidate scaffolds for next-gen anti-infectives.
Mechanistically, cecropins are positively charged, α-helical peptides that disrupt bacterial membranes by binding and forming pores, rapidly compromising integrity—especially in Gram-negative organisms. Beyond direct killing, multiple studies show LPS binding/neutralization and broader immunomodulatory effects, suggesting dual antibacterial and anti-inflammatory potential.
Translational signals are encouraging yet early: cecropins (and engineered derivatives) show activity against pathogens and biofilms, and have been explored in topical/wound contexts; however, robust, modern human trials specific to cecropins are limited, and most peptide-therapeutic progress comes from the broader AMP class. Position cecropins as investigational scaffolds within anti-infective research rather than patient-ready therapies.
Celexir delivery & specs: supplied as lyophilized vials (research grade) with >98% purity, −20 °C storage, and CoA/MSDS for lab workflows; dosing is model-dependent. This confines use to controlled research settings while enabling standardized handling and reproducibility.